Profile data is unavailable for this security.
About the company
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the business of oncolytic immunotherapy to treat cancer patients. The Company is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types. The Company's lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R and human GM-CSF. RP1 is designed to treat more immune responsive tumor types. The Company's pipeline product candidates include RP2 and RP3. The encoded GALV-GP R protein enhances the tumor killing ability of the virus and increases immunogenic cell death. RP2 is an additionally encodes an anti-CTLA-4 antibody has designed to treat more immunologically silent tumors. RP3 expresses a pair of immune costimulatory pathways activating ligands, CD40L and 4-1BBL, to further increase the potency of the immune responses to treat immunologically cold tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-209.96m
- Incorporated2017
- Employees284.00
- LocationReplimune Group Inc500 Unicorn Park DrWOBURN 01801-3377United StatesUSA
- Phone+1 (781) 222-9600
- Fax+1 (302) 655-5049
- Websitehttps://www.replimune.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fibrobiologics Inc | 0.00 | -19.06m | 376.92m | 10.00 | -- | 300.04 | -- | -- | -0.9149 | -0.9149 | 0.00 | 0.0384 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -60.47 | 0.1012 | -- | -- | -- | -272.15 | -- | -- | -- |
| Adaptive Biotechnologies Corp | 170.28m | -225.25m | 377.24m | 709.00 | -- | 1.22 | -- | 2.22 | -1.56 | -1.56 | 1.18 | 2.13 | 0.2244 | 5.23 | 4.36 | 240,163.60 | -29.69 | -19.69 | -34.13 | -22.06 | 55.63 | 67.18 | -132.32 | -122.27 | 4.50 | -- | 0.00 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
| Cibus Inc | 1.82m | -267.63m | 377.92m | 183.00 | -- | 1.07 | -- | 207.99 | -22.63 | -22.63 | 0.1769 | 14.27 | 0.0064 | -- | -- | 9,928.96 | -119.13 | -86.28 | -135.32 | -96.45 | 2.31 | -- | -18,582.22 | -792.07 | -- | -3.70 | 0.0049 | -- | 1,057.33 | 50.41 | -1,484.44 | -- | 18.53 | -- |
| iTeos Therapeutics Inc | 12.60m | -112.64m | 378.86m | 157.00 | -- | 0.6585 | -- | 30.08 | -3.15 | -3.15 | 0.3522 | 16.05 | 0.0177 | -- | 2.82 | 80,222.93 | -15.84 | 5.84 | -16.81 | 7.02 | -- | -- | -894.35 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
| Anika Therapeutics Inc | 166.66m | -82.67m | 379.20m | 357.00 | -- | 1.79 | -- | 2.28 | -5.64 | -5.64 | 11.37 | 14.48 | 0.5378 | 1.48 | 4.72 | 466,840.30 | -26.68 | -5.41 | -29.48 | -5.87 | 61.85 | 60.70 | -49.60 | -12.60 | 3.76 | -- | 0.00 | -- | 6.67 | 9.56 | -456.34 | -- | 3.11 | -- |
| Alto Neuroscience Inc | 0.00 | -36.31m | 381.75m | 63.00 | -- | -- | -- | -- | -1.42 | -1.42 | 0.00 | 2.73 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.1238 | -- | -- | -- | -31.02 | -- | -- | -- |
| PepGen Inc | 0.00 | -78.63m | 382.75m | 64.00 | -- | 2.60 | -- | -- | -3.30 | -3.30 | 0.00 | 4.55 | 0.00 | -- | -- | 0.00 | -43.62 | -- | -48.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Biomea Fusion Inc | 0.00 | -117.26m | 386.53m | 103.00 | -- | 2.28 | -- | -- | -3.46 | -3.46 | 0.00 | 4.72 | 0.00 | -- | -- | 0.00 | -71.23 | -- | -81.63 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
| Neurogene Inc | 0.00 | -36.32m | 388.55m | 91.00 | -- | 2.08 | -- | -- | -29.21 | -29.21 | 0.00 | 14.51 | 0.00 | -- | -- | 0.00 | -21.46 | -32.70 | -23.85 | -34.73 | -- | -- | -- | -- | -- | -- | 0.0006 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
| Replimune Group Inc | 0.00 | -209.96m | 388.58m | 284.00 | -- | 0.9218 | -- | -- | -3.16 | -3.16 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | -34.66 | -26.12 | -36.63 | -27.31 | -- | -- | -- | -- | -- | -- | 0.1436 | -- | -- | -- | -47.65 | -- | 75.59 | -- |
| Organogenesis Holdings Inc | 433.14m | 4.95m | 393.25m | 862.00 | 81.07 | 1.40 | 19.36 | 0.9079 | 0.0368 | 0.0368 | 3.27 | 2.12 | 0.9526 | 4.02 | 5.05 | 502,482.60 | 1.09 | 5.46 | 1.31 | 6.90 | 75.42 | 74.94 | 1.14 | 4.81 | 2.44 | 9.05 | 0.1989 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
| Lexicon Pharmaceuticals Inc | 1.21m | -177.12m | 393.98m | 285.00 | -- | 4.21 | -- | 326.95 | -0.7975 | -0.7975 | 0.0055 | 0.3802 | 0.0057 | -- | 2.32 | 4,228.07 | -83.60 | -24.41 | -96.00 | -29.01 | 90.95 | 98.49 | -14,698.67 | -84.92 | 5.58 | -13.11 | 0.5166 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
| ADC Therapeutics SA | 69.56m | -240.05m | 394.49m | 273.00 | -- | -- | -- | 5.67 | -2.94 | -2.94 | 0.8528 | -1.80 | 0.1645 | 0.179 | 1.42 | 254,791.20 | -55.47 | -48.41 | -67.39 | -55.63 | 96.36 | -- | -337.16 | -308.62 | 4.73 | -4.70 | 1.55 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
| Tourmaline Bio Inc | 0.00 | -42.12m | 395.21m | 44.00 | -- | 1.53 | -- | -- | -10.18 | -10.18 | 0.00 | 10.08 | 0.00 | -- | -- | 0.00 | -20.85 | -- | -21.74 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
| Heron Therapeutics Inc | 127.04m | -110.56m | 398.37m | 126.00 | -- | -- | -- | 3.14 | -0.8695 | -0.8695 | 0.9494 | -0.2261 | 0.5367 | 1.35 | 2.26 | 1,008,286.00 | -46.70 | -53.55 | -71.00 | -71.24 | 48.75 | 52.52 | -87.02 | -170.12 | 1.84 | -- | 1.29 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
Data as of Apr 25 2024. Currency figures normalised to Replimune Group Inc's reporting currency: US Dollar USD
68.54%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 31 Dec 2023 | 9.55m | 15.55% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 6.55m | 10.67% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 6.49m | 10.57% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 4.39m | 7.15% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 3.91m | 6.37% |
| Redmile Group LLCas of 31 Dec 2023 | 3.87m | 6.30% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.67m | 4.35% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2023 | 2.20m | 3.58% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 1.32m | 2.16% |
| Geode Capital Management LLCas of 31 Dec 2023 | 1.15m | 1.87% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
